HK1210779A1 - 酪氨酸激酶抑制劑 - Google Patents

酪氨酸激酶抑制劑

Info

Publication number
HK1210779A1
HK1210779A1 HK15111588.8A HK15111588A HK1210779A1 HK 1210779 A1 HK1210779 A1 HK 1210779A1 HK 15111588 A HK15111588 A HK 15111588A HK 1210779 A1 HK1210779 A1 HK 1210779A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tyrosine kinase
brutons tyrosine
brutons
kinase
Prior art date
Application number
HK15111588.8A
Other languages
English (en)
Inventor
Niala Bhagirath
Romyr Dominique
Joshua Kennedy-Smith
Francisco Javier Lopez-Tapia
Eric Mertz
Qi Qiao
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1210779A1 publication Critical patent/HK1210779A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15111588.8A 2012-10-26 2015-11-25 酪氨酸激酶抑制劑 HK1210779A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718746P 2012-10-26 2012-10-26
US201361831443P 2013-06-05 2013-06-05
PCT/EP2013/072123 WO2014064131A2 (en) 2012-10-26 2013-10-23 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
HK1210779A1 true HK1210779A1 (zh) 2016-05-06

Family

ID=49488574

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111588.8A HK1210779A1 (zh) 2012-10-26 2015-11-25 酪氨酸激酶抑制劑

Country Status (12)

Country Link
US (1) US20150284394A1 (zh)
JP (1) JP6139690B2 (zh)
KR (1) KR20150060839A (zh)
CN (1) CN104662024B (zh)
AR (1) AR093123A1 (zh)
BR (1) BR112015007513A2 (zh)
CA (1) CA2881070A1 (zh)
HK (1) HK1210779A1 (zh)
MX (1) MX2015002975A (zh)
RU (1) RU2619465C2 (zh)
TW (1) TW201422619A (zh)
WO (1) WO2014064131A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CA2960401C (en) * 2014-10-06 2022-07-26 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
AR102427A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Derivados de carbazol inhibidores de quinasas
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
WO2020234780A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP4051679A1 (en) * 2019-10-30 2022-09-07 Biogen MA Inc. Condensed pyridazine or pyrimidine as btk inhibitors
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN113735859A (zh) * 2021-08-12 2021-12-03 安徽医科大学 一种激酶抑制剂
CN113583007B (zh) * 2021-08-31 2022-06-10 山东大学 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用
WO2023086521A1 (en) * 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
RS54181B9 (sr) * 2005-12-13 2020-01-31 Incyte Holdings Corp Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
WO2007125315A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP2010170080A (ja) * 2008-12-24 2010-08-05 Sanyo Electric Co Ltd レンズ装置、撮影装置
PT2473049T (pt) * 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors

Also Published As

Publication number Publication date
TW201422619A (zh) 2014-06-16
RU2619465C2 (ru) 2017-05-16
CA2881070A1 (en) 2014-05-01
CN104662024A (zh) 2015-05-27
AR093123A1 (es) 2015-05-20
CN104662024B (zh) 2016-12-07
KR20150060839A (ko) 2015-06-03
RU2015117949A (ru) 2016-12-20
WO2014064131A2 (en) 2014-05-01
WO2014064131A3 (en) 2014-10-16
JP6139690B2 (ja) 2017-05-31
US20150284394A1 (en) 2015-10-08
BR112015007513A2 (pt) 2017-07-04
MX2015002975A (es) 2015-06-22
JP2015535226A (ja) 2015-12-10

Similar Documents

Publication Publication Date Title
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1211293A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
HK1194381A1 (zh) 酪氨酸激酶抑制劑
HK1197060A1 (zh) 酪氨酸激酶抑制劑
HK1186186A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1224173A1 (zh) 布魯頓氏酪氨酸激酶抑制劑和 抑制劑的組合
HK1208803A1 (zh) 布魯頓酪氨酸激酶抑制劑的晶形
HK1210161A1 (zh) 用作布魯頓酪氨酸激酶 抑制劑的雜芳族化合物
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮
HK1210779A1 (zh) 酪氨酸激酶抑制劑
PL2710005T3 (pl) Inhibitory kinazy tyrozynowej
HK1200816A1 (zh) 布魯頓酪氨酸激酶抑制劑
HK1206624A1 (zh) 用於造血動員的布魯頓酪氨酸激酶抑制劑
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2903970A4 (en) SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1212975A1 (zh) 作為布魯頓氏酪氨酸激酶抑制劑的噻唑衍生物
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211022